Nanoparticle drug delivery is an emerging field of life science that promises to revolutionize the field of medicine and medical technology.
Global Nanoparticle Drug Delivery Market, Dosage, Price and Clinical Pipeline Outlook 2028 Report Highlights:
- Global Nanoparticle Drug Delivery Market Opportunity > USD 300 Billion by 2028
- Nanoparticle Drug Deliver Price & Dosage Insight By Therapeutic (Cancer, Anemia, Autoimmune Diseases, Neurological Disorders)
- Nanoparticle Therapeutics Approved Drugs Sales Analysis & Forecast Till 2028
- Global Nanoparticle Drugs Clinical Pipeline Insight By Phase, Company & Indication
- Nanoparticle Drug Delivery - Market Trend & Patent Distribution Analysis
Download Report: https://www.kuickresearch.com/ccformF.php?t=1646380145
Nanoparticle drug delivery is an emerging field of life science that promises to revolutionize the field of medicine and medical technology. The key advantage which is associated with the development of nanoparticle drug is that it offers excellent efficacy even in minute dosage without compromising the safety. This uniqueness associated with nanoparticle drug delivery systems has surged pharmaceutical companies to develop modern therapeutics using nanoparticle using its promising potential in the future of drug delivery method. Till date, more than 40 nanoparticle drugs have been approved by regulatory bodies which are indicated for wide range of diseases including cancer, anemia, neurological disorders, autoimmune diseases, and others.
The promising response of the nanoparticle drugs has further led to the development of robust clinical pipeline of drugs. The major drugs in clinical development include NK105, CYT-6091, MBP-426, ThermoDox, Nanoplatin, Endotag-1, Nanoplatin, and others. The large number of ongoing clinical trials and the encouraging response of these drugs in clinical studies suggest the promising future of nanoparticle based drugs in the market. CNM-Au8 developed by Clene is one of the most promising candidates in the development for the neurodegenerative diseases and is currently present in phase-II/III clinical trial. CNM-Au8 is a gold nanocrystal suspension, developed to increase cellular energy production and utilization to restore neuronal health.
Although the nanoparticle drug offers several advantages over conventional drug delivery methods, the development of these drugs can be lengthy and expensive process. To overcome this, start-ups and small biotech companies developing innovative nanotechnology rely heavily on funding and adopting strategic alliances to advance candidates into proof-of-concept studies and towards commercialization. For instance in 2021, NexImmune collaborated with Yale’s University of Immunobiology which will focus on the use of NexImmune’s direct injection, artificial antigen presenting cells (AIM NJ) with regards to the regulation of autoimmune diabetes (Type-1 diabetes). Further, NaNotics also announced research collaboration with Mayo Clinic to develop a NaNot that target the soluble form of PD-L1, a tumor generates immune inhibitor. As a part of collaboration, NaNotics will provide its core nano-depletion platform and Mayo Clinic will provide an antibody of its own design against PD-L1, which will be specific to sPD-L1 once incorporated into Nanot.
As per our report findings, it is expected that global nanoparticle drug delivery market will surpass US$ 300 Billion by 2028. The major drivers of the global market include its application in various therapeutic areas, increasing research and development activities about nanorobots in this segment, and significant investments in clinical trial by public as well as government sector. Currently, more than 500 clinical trials are ongoing globally which are evaluating novel nanomedicine drug delivery in wide range of therapeutic indications. The coming years is expected to witness rapid approval of the drugs in the market which will further boost the growth of market. In addition to this, emergence of enhanced technologies such as 4D printing smart biosystems for nanomedicines also suggests the promising future of nanoparticles in drug delivery during the forecast period.
The report provides complete details about the usage and adoption rate of nanomedicines in various therapeutic verticals and regions. With that, key stakeholders can know about the major trends, drivers, investments, vertical player’s initiatives, government initiatives towards the nanomedicine adoption in the upcoming years along with the details of commercial drugs available in the market. Moreover, the report provides details about the major challenges that are going to impact on the market growth. Additionally, the report provides in-depth analysis on the ongoing clinical trials in the market. The major companies mentioned in the report include Abbvie, Amgen, Pfizer, Tandem Nano, Horizon Therapeutics, Biogen, Bristol Myers Squibb, Nanobiotix, and others.
For More Information Related To Report Contact:
Neeraj Chawla
Research Head
Kuick Research
+919810410366